Bold opening: A new oral therapy is being tested in a major global trial for early Alzheimer’s disease, and the implications could reshape how the condition is managed. But here’s where it gets controversial: does a multi-mechanistic PDE5 inhibitor truly modify the disease, or does it mainly offer symptomatic relief? Read on to understand what POLARIS-AD is testing, who qualifies, and what the initial data hint at.
A large, international phase 3 study named POLARIS-AD is currently underway to evaluate AR1001 (mirodenafil) for safety and efficacy in more than 1,500 individuals with mild cognitive impairment (MCI) or early Alzheimer’s disease (AD). This trial is designed as a 52-week, parallel-group, double-blind, placebo-controlled study, enrolling participants across multiple regions and aiming to generate topline results in 2026. The trial’s design is biomarker-agnostic, focusing on clinical outcomes while also collecting biomarker data to enrich understanding of AR1001’s potential effects on disease biology.
Baseline characteristics presented at the 18th Clinical Trials on Alzheimer’s Disease Conference (CTAD) in San Diego show that the enrolled cohort had a mean CDR-SB score of 3.45 (±1.70) at entry, with a mean ADAS-Cog13 score of 27.75 (±8.02). Other baseline measures included an Amsterdam IADL score of 72 (±20.72), a GDS score of 1.6 (±1.81), and an MMSE score of 24.01 (±2.70).
Led by Neils Prins, MD, PhD, Progress Clinical Research in The Netherlands coordinated screening of 4,025 potential participants, ultimately enrolling 1,535 individuals (about 62%). The majority of enrollees came from North America (658), with participants also from Korea (200), the United Kingdom (49), the European Union (502), and China (126). The cohort was 55% female, had a mean age of 73, and racial composition was 72.3% White (including 11.7% Hispanic/Latino), 22% Asian, and 2.7% Black or African American.
Researchers describe POLARIS-AD as among the largest global enrollments for an oral, multi-mechanistic therapeutic in Alzheimer’s disease. The study’s biomarker-agnostic approach broadens access and supports the creation of what may be the largest CSF sample repository to date. Baseline demographics and cognitive profiles align with other landmark AD trials. Interim safety data have shown no new safety signals, and recruitment into the extension phase has been robust. Top-line results are anticipated in 2026.
Eligibility criteria required adults aged 55–90 with MCI or mild AD dementia, defined as NIA-AA 2018 stage 3–4. Confirmed amyloid positivity could be established via visual and quantitative PET (Centiloid > 30 CL where available) or CSF assays, including the Lumipulse®G amyloid-β (1-42/1-40) ratio and Roche Elecsys® assays (t-tau/amyloid-β (1-42) and pTau-181/amyloid-β (1-42)). Additional inclusion criteria encompassed a recent cognitive decline within five years, an MMSE score above 20, a CDR-Global score of 0.5 or 1, and a RBANS score no higher than 85.
AR1001 acts as a second-generation PDE5 inhibitor with the ability to cross the blood-brain barrier. Prior phase 2 data explored AR1001 as monotherapy in mild to moderate AD, comparing placebo, 10 mg, and 30 mg doses. In a subgroup not receiving other AD therapies, 30 mg AR1001 daily for 26 weeks yielded a statistically significant improvement of 4.019 points on the ADAS-Cog-13 from baseline (P = .012). Among those assigned to 30 mg, about 66% were on concomitant AD meds, suggesting the cognitive benefit may extend beyond combination therapy.
Although the phase 2 study did not meet its primary endpoint for the full population, the monotherapy subgroup showed meaningful cognitive gains and reductions in biomarkers like plasma ptau181 and ptau217. These biomarker shifts provide a strong biological rationale for continuing in the ongoing POLARIS-AD phase 3 trial.
Given AR1001’s ability to penetrate the brain and its multi-pathway targeting potential, researchers are not only tracking cognitive outcomes but also changes in neurodegenerative biomarkers to capture possible disease-modifying effects beyond symptomatic relief.
For ongoing updates on CTAD 2025 coverage and further details about AR1001, see NeurologyLive’s coverage and the referenced CTAD materials.
Key references include: the POLARIS-AD global enrollment report presented at CTAD; phase 2 data in mild-to-moderate AD showing monotherapy benefits and biomarker changes; and the phase 3 trial protocol registration (NCT05531526). These sources collectively frame the current evidence base and the rationale for the phase 3 investigation.
Would you like this rewritten version to emphasize practical implications for patients or to include a brief explainer of how PDE5 inhibitors might affect Alzheimer’s biology for beginners? Also, would you prefer a version that foregrounds potential controversies or policy implications related to fast-tracking cognitive-improvement drugs?
